Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016 Feb 13; 387(10019):661-670.

View in: PubMed

subject areas

Adolescent
Anemia, Sickle Cell
Antisickling Agents
Blood Flow Velocity
Blood Transfusion
Cerebrovascular Circulation
Child
Child, Preschool
Combined Modality Therapy
Drug Substitution
Female
Humans
Hydroxyurea
Male
Stroke
Treatment Outcome
Ultrasonography, Doppler, Transcranial

authors with profiles

Sherron M. Jackson
Robert J. Adams